BCL2L1 and cancer: Several approaches have been devised to selectively deprive cancer cells of the expression of BcL-xL, including the use of splice-switching oligonucleotides that mask the usage of the BcL-xL splice site, resulting in the re-sensitization of the cancer cells to chemotherapy [18,19].